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Only a few years ago the American Society of Assisted Reproductive Medicine (ASRM), the European Society for
Human Reproduction and Embryology (ESHRE) and the British Fertility Society declared preimplantation genetic
screening (PGS#1) ineffective in improving in vitro fertilization (IVF) pregnancy rates and in reducing miscarriage
rates. A presumably upgraded form of the procedure (PGS#2) has recently been reintroduced, and is here assessed in a
systematic review. PGS#2 in comparison to PGS#1 is characterized by: (i) trophectoderm biopsy on day 5/6
embryos in place of day-3 embryo biopsy; and (ii) fluorescence in-situ hybridization (FISH) of limited chromosome
numbers is replaced by techniques, allowing aneuploidy assessments of all 24 chromosome pairs. Reviewing the
literature, we were unable to identify properly conducted prospective clinical trials in which IVF outcomes were
assessed based on “intent to treat”. Whether PGS#2 improves IVF outcomes can, therefore, not be determined.
Reassessments of data, alleged to support the efficacy of PGS#2, indeed, suggest the opposite. Like with PGS#1,
the introduction of PGS#2 into unrestricted IVF practice again appears premature, and threatens to repeat the
PGS#1 experience, when thousands of women experienced reductions in IVF pregnancy chances, while expecting
improvements. PGS#2 is an unproven and still experimental procedure, which, until evidence suggests otherwise,
should only be offered under study conditions, and with appropriate informed consents.
Keywords: Preimplantation genetic diagnosis (PGS), Assisted reproduction (ART), In vitro fertilization (IVF),
Trophectoderm biopsy, Blastocyst stage embryo transferBackground
In July 2007 Mastenbroek et al. published one of the most
important papers in the history of in vitro fertilization
(IVF) when they reported that preimplantation genetic
screening (PGS) in women of advanced age not only failed
to improve but actually diminished ongoing IVF preg-
nancy and live birth rates [1]. Despite some valid criti-
cisms of the study [2], the historic importance of this
paper stems from its effects on clinical practice since its
publication reduced the worldwide utilization of PGS in
attempts to improve IVF outcomes, as indicated by U.S.
[3] and European data from a 10-year ESHRE report,
which demonstrated a first decline in PGS numbers [4]
in 2007, the year Mastenbroek’s paper appeared in print
[1]. For the rest of this communication this initial form of
PGS will be described as PGS#1.* Correspondence: ngleicher@thechr.com
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unless otherwise stated.Because the basic hypothesis of PGS that the transfer
of only euploid embryos should improve IVF outcomes is
so attractively logical, up to publication of Mastenbroek’s
paper, proponents of PGS#1 had convinced a majority of
the worldwide IVF community that it represented a valid
approach towards improving IVF outcomes. What PGS#1,
however, really accomplished was to reduce pregnancy
chances for a significant proportion of women utilizing
the procedure, mostly older women, without offering
benefits to others [5-7]. PGS#1, thus, achieved the unique
notoriety of becoming the first ever widely introduced
routine IVF practice, which actually harmed IVF cycle
outcomes. By reducing this practice, the 2007 publica-
tion by Mastenboek et al. established its historical
prominence [1].
Mastenbroek et al., however, were not the first to notice
the futility of PGS#1: Earlier, Belgian investigators failed to
detect IVF outcome benefits from PGS#1 in three smaller
clinical trials [8-10]. Further analyzing the 2004 paper
by Staessen et al. [8], we started to suspect that PGS#1l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pregnancy chances. Our suspicion was raised because
the study’s older patient population produced significantly
lower embryo numbers for transfer and an almost sta-
tistically significant trend towards lower pregnancy
rates (P = 0.06) in association with PGS#1.
We, therefore, were not surprised by the 2007 study of
Mastenbroek et al. [1]. A paper, outlining our suspicion,
and including a reanalysis of the Belgian data, was, however,
only accepted (in expedited review) after Mastenbroek’s
paper had appeared [11]. Our suspicion that pregnancy
chances of older women are actually hurt by the procedure
was subsequently repeatedly demonstrated [5-7]. The
importance of these age-related findings was reemphasized
by the fact that, at least in Europe, the primary indication
for PGS#1 was advanced female age [4].
Just a few years later, history appears to repeat itself: A
supposedly improved version of PGS (PGS#2), claiming
outcome benefits for IVF, is now, once again, being pro-
moted. This reintroduction of PGS in the form of PGS#2
is mostly based on allegedly improved techniques and
technologies, with ability to diagnose aneuploidies more
accurately.
In a review of PGS#1 we recently reached the conclu-
sion that the failure of PGS#1, likely, was not, as suggested
by proponents of PGS#2, the consequence of inadequate
PGS#1 techniques and technologies but, primarily, due to
incorrect patient selection. We, therefore, cautioned from
uncritically accepting the notion that improvements in
PGS#1 techniques and technologies, alone, would improve
IVF outcomes [12].
We here present a systematic review of published PGS#2
experiences in an attempt to determine whether so far
reported results with PGS#2, indeed, do improve clinical
pregnancy and delivery rates and/or reduce miscarriage
rates in association with IVF.
Methods
We reviewed the medical literature via PubMed and
Medline searches under appropriate keyword and phrases
up to year-end 2013. Keywords included < preimplantation
genetic diagnosis > and the abbreviating < PGD>; <preim-
plantation genetic screening > and the abbreviation <
PGS>; the phrases < genetic screening with in vitro
fertilization/IVF > and < genetic diagnosis with in vitro
fertilization/IVF>. We also searched under the phrases <
arrays in IVF>, <comparative genomic hybridization
in IVF>, <comprehensive chromosome screening in
IVF > and <24 chromosome copy analysis in IVF > .
The primary review was performed by one of the
authors (N.G.), with the other two authors reviewing
selected publications in conjunction with internal ree-
valuations of published data. The primary review of
the literature revealed 93 relevant articles. Amongstthose, 39 were chosen as reflective of published data
on PGS#2, and as references with relevance to the
presentation of context. Five of these references, providing
context, were added based on suggestions received during
the manuscript review process. It is important to note that
all published papers in the English literature addressing
PGS#2 during the search years were reviewed. This study
presents all published data on PGS#2, independent of our
quality assessment. In addition, we reviewed reference lists
of reviewed papers for additional appropriate articles.
Since this literature review did not reveal even a single
study in which PGS#2 was evaluated based on “intent to
treat” (i.e., with reference point IVF cycle start), this review
cannot report a metaanalysis of reported data. While this
finding, alone, suggests that so far available PGS#2 data
are insufficient to support the uncontrolled utilization of
PGS#2 as a routine feature of IVF practice, our research
did discover published studies, claiming to be represent
results of clinical trials demonstrating outcome benefits
for IVF following utilization of PGS#2. Since our evalu-
ation of these studies disagreed with the authors’ conclu-
sions, two such studies are here discussed in detail.
To make sure no relevant studies were overlooked,
we also reviewed all currently registered PGS trials,
cross-referencing the names of principal investigators
under above noted key words and phrases in our litera-
ture search.
Results
As noted above, we were unable to find even one appro-
priately performed prospectively randomized clinical trial,
which assessed IVF outcomes with use of PGS#2 based on
“intent to treat.” Also discussed in more detail below, this
prohibits a statistically valid assessment of PGS#2 in its
utility to improve IVF outcomes by meta-analysis. We
made this observation already in 2012, noting at the
time that such studies would only unlikely appear in
the literature in the foreseeable future since among all
formally registered ongoing clinical trials on the sub-
ject, none appeared to use properly designed statistical
methodologies, including analysis of IVF outcomes by
“intent to treat” [12].
Here obtained results, therefore, are not necessarily
surprising. Only one then registered clinical trial has,
since, been completed in 2012, has been reported, and will
be discussed in detail below. The statistical methodologies
utilized in this trial fully confirmed our then voiced
concerns [12]. Absence of properly designed clinical
trials is especially noteworthy as patient surveys suggest
willingness to participate in such trials [13].
Though results of this systemic review, thus, have
failed to demonstrate adequate supportive evidence for
the clinical utilization PGS#2 outside of experimental
frameworks, this review, nevertheless, offers additional
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of PGS#2, presented below in the discussion section of
this manuscript.
Discussion
Two studies, receiving extraordinary attention for claiming
outcome benefits for PGS#2, appeared in print during
2013. In addition, at least one editorial opinion was
supportive of PGS#2 [14], though others [15] and we
[16] disagreed. In this discussion section we, therefore,
pay special attention to these two studies, partially
reassessing their data, as reported by the investigators.
How PGS#2 is misrepresented
To understand the importance of outcome calculations
in assessing the efficacy of PGS#2 based on “intent to
treat”, differences between PGS#1 and PGS#2 have to be
clearly understood. A few major technical and methodo-
logical changes differentiate between the two:
(i) PGS#2 relies on trophectoderm biopsy of embryos
on days 5–6 after fertilization, while PGS#1 relied on
day-3 blastomere biopsy. One important difference be-
tween these two techniques, therefore, lies in trophecto-
derm biopsy mandating embryo culture to days 5/6.
Unless viable embryos reach blastocyst stage, patients
are not even given a chance of embryo biopsy and
chromosomal analysis in association with PGS#2. Not
all embryos, however, reach blastocyst stage. Especially
embryos from older women and younger females with
prematurely low ovarian reserve often do not. Only better
prognosis patients do culture successfully in vitro up to
days 5/6. This fact is, indeed, so well known that some
IVF centers utilize culture to blastocyst stage as a method
of embryo selection, allowing the “fittest” to survive.
Trophectoderm biopsy in association with PGS#2, there-
fore, defines the patient population undergoing PGS#2 as
distinctively different from earlier PGS#1 populations.
Even in older women and younger women with low
ovarian reserve many more embryos survive in in vitro
laboratory culture to day-3 after fertilization, where em-
bryo biopsy was preformed for PGS#1, than to days 5/6,
required for trophectoderm biopsy. Therefore, significantly
more of such females would reach embryo transfer on
day-3 than on days 5/6. Though disputed by some, there is,
in fact, at least good anecdotal evidence that some embryos,
which will not survive in vitro culture in the laboratory
to days 5/6, if transferred on day-3 after fertilization, may
still be able to establish normal pregnancies [12,15,16].
PGS#2 and PGS#1 outcomes can, and should, there-
fore, not be compared without statistically adjusting for
difference in patient population. PGS#2 patients are clearly
favorably selected in comparison.
(ii) Not only whether embryos survive to blastocyst stage
in culture matters; how many survive matters as well.Older women and younger females with prematurely
diminished ovarian reserve reach blastocyst stage with
greatly diminished embryo numbers. Their risk of not
reaching embryo transfer is, therefore, not only increased
because so many of their embryos do not survive in the la-
boratory to days 5/6 but also because only comparatively
few do survive to blastocyst stage. The fewer embryos a
patient has available for trophectoderm biopsy and
chromosomal evaluation, the higher the risk that all of
the patient’s embryos will be aneuploid and, therefore,
not available for embryo transfer.
Those patients who do reach embryo transfer in PGS#2
are, thus, automatically twice favorably selected.
This is a principal reason why all so far published
PGS#2 studies, including those claiming outcome benefits
for IVF, have been reporting outcomes in highly favorably
selected patients. Only two so far published small studies
have, however, pointed out this fact, one a small clinical
trial of PGS#2 [17] and a small case control study, utilizing
PGS#1, from our center [18]. That PGS#2, thus, automat-
ically excludes significant patient populations, including
older women who, in the initial utilization as PGS#1
represented the primary target population [4] is, there-
fore, neither communicated to the scientific community
nor to patients receiving such treatments.
(iii) Finally, to define pregnancy outcomes for PGS#2
statistically correctly, it is essential to assess pregnancy
rates by “intent to treat”. This means that pregnancy
rates have to be calculated with denominator cycle start
rather than embryo transfer. Yet, every single paper so far
published in the literature, claiming any kind of outcome
benefit for PGS#2, reported pregnancy outcomes with
reference point embryo transfer. All of these studies,
therefore, breach one of the most basic rules of statistical
outcome reporting in IVF and, simply, misrepresent
outcomes.
Misleading outcome reporting is, unfortunately, increas-
ingly prevalent in the U.S., and has also contaminated
federally mandated national IVF reporting [19]. Amongst
a small number of U.S. clinics recently reported to artifi-
cially increase their reported live births rates we, as part of
this investigation, indeed, noted a doubling of the number
of PGS cycles during the 5-year study period to 8% of
all center cycle activity, versus 4% for all other reporting
clinics (Kushnir VA, Barad DH and Gleicher N, unpub-
lished data).
(iv) While PGS#1 used fluorescence-in situ-hybridization
(FISH) of a restricted number of chromosomes, likely the
most profound advance in technology in PGS#2 is the
ability to assess a complete chromosome complement via
a 24-pair chromosome copy number analysis. Various
companies and their respective assays now compete in the
market place, with accuracy (i.e., false-positive and –nega-
tive rates) for most systems remaining to be determined.
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from a recently published study [20], though how individ-
ual testing platforms compare to each other also, still,
needs to be established.
(v) Blastocyst stage in vitro culture has recently also
been reported associated with two significant additional
potential risks: In various small animal IVF models pro-
longed embryo culture has been demonstrated to lead
to significant epigenetic changes, interfering with im-
printing maintenance and DNA demethylation dynamics
[21-23]. In addition, increasing human evidence sug-
gests that blastocyst stage cultures are associated with
increased premature delivery risk in comparison to
earlier stage embryo transfers [24,25]. Combined, these
observations raise further questions about PGS#2, which
is dependent on blastocyst stage embryo biopsy.
A study comparing day-3 and days 5/6 embryo biopsies
The study by Harton et al. [20] reported outcomes of
PGS#2 for embryo biopsies performed on days-3 or
days-5/6, utilizing the same newly developed array, com-
parative genomic hybridization technique (BlueGnome),
which allows for analysis of a complete 24 chromosome
complement on both biopsy days. This, therefore, is the
first study comparing aneuploidy in a complete chromo-
some complement, performing either day-3 or days-5/6
embryo biopsies, utilizing one of the newly developed
testing platforms.
While there are technical differences between these
newly reported testing techniques, and comparative
studies between different commercial platforms are not
available, they share the claim that by allowing for as-
sessments of a complete chromosome complement they
are more accurate in determining embryo aneuploidy
than the prior (exclusively on post-fertilization d-3)
utilized FISH. Results of this study, in at least general
terms, should therefore also be applicable to other reported
platforms allowing for aneuploidy testing of a complete
chromosome complement.
An analysis, comparing the same aneuploidy testing
technique on days 3 and 5/6 after fertilization was overdue
since the superiority in accuracy of aneuploidy diagnosis,
claimed for these new diagnostic platforms appears
compelling but has remained clinically unproven. To
maintain its alleged superiority over PGS#1, days-5/6
trophectoderm biopsy, this key component of PGS#2, has
to establish its superiority over day-3 embryo biopsy.
Recognizing the statistical and design weaknesses of
this study, including lack of patient randomization to
day-3 and days-5/6 biopsies, and unadjusted participation
of multiple IVF centers with greatly varying IVF treatment
protocols and patient populations, this study’s outcomes
have to be interpreted with considerable caution. If data
from this study are, however, considered “good enough”for proponents of PGS#2, fairness suggests that these data
should also be available to support arguments of potential
skeptics.
If the study is viewed in this way, it does offer poten-
tially important new insights into efficacy of PGS#2.
Those insights, however, in fact do not support efficacy
of PGS#2 in improving IVF outcomes. A careful analysis
of reported data, actually, offers further support for lack
of therapeutic efficacy of PGS in general, and PGD#2 in
particular.
Here is why: Reflected in the title of the paper, the
main conclusion of the study was that, with utilization
of their new array comparative genomic hybridization
technique, up to age 42 years (and lesser extend above
age 42), PGS#2 significantly diminished the effects of
maternal age on embryo implantation and pregnancy
rates. This conclusion was, however, once again based on
implantation and pregnancy rates with reference embryo
transfer rather than cycle start. In absence of an outcome
analysis based on “intent-to-treat”, reported results, there-
fore, have to be viewed as statistically suspicious.
The authors also erred in concluding that widely reported
declining rates of IVF success with advancing female age
primarily have to be caused by aneuploidy since such an
interpretation ignores that in women with poor ovarian
reserve and/or small embryo numbers, embryo culture to
days-5/6 blastocyst stage and/or embryo biopsy may have
significantly contributed to their IVF failures [12,15].
The study does, however, offer some interesting add-
itional findings: Aneuploidy rates were 21.4% higher
(70-.6% vs. 49.2%) if embryos were biopsied on day-3,
offering further evidence for a significant degree of self
correction of embryos between days-3 and 5/6, as pre-
viously suggested [26], and often proposed as argument
against day-3 embryo biopsies. Yet, implantation rates,
even in those selected women who did reach embryo
transfer, improved only by 9.6% (39.6% to 49.2%) in favor
of days-5/6 embryo biopsies.
Since, as even the authors note in their manuscript,
“some” women did not reach days-5/6 embryo transfer,
the study raises the question whether the reported im-
provement in implantation rates between day-3 and
days-5/6 biopsies would still be statistically significant if
the outcome analysis had been performed by “intent-to-
treat” (i.e. with reference cycle start).
The same question also arises in regards to presented
data on pregnancy loss. Here, miscarriages after day-3
biopsy occurred in 9.9%, only 2.0% above the 7.9% for
days-5/6 biopsies. Considering that almost a third of
patients in both groups were above age 40 years old,
both of these miscarriage rates appear unusually low.
Analysis by “intent-to-treat” would, almost with certainty,
not reveal a reduction in miscarriage rates for days-5/6
over day-3 biopsies.
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presented in total, like implantation and miscarriage
rates, but stratified by age groups, these data are somewhat
difficult to interpret. They are also presented with two
different reference points, per embryo biopsy (i.e., patients
reaching embryo biopsy) and per embryo transfer (i.e.,
patients having at least 1 euploid embryo). Both reference
points are, of course, removed from “intent to treat” since
not every patient reaches embryo biopsy, and not every
embryo reaching embryo biopsy will also be euploid and,
therefore, transferrable.
The authors’ mode of data presentation, however, actu-
ally accentuates the importance of analysis by “intent to
treat” since it well demonstrates that the reference point of
embryo transfer is farthest removed from “intent to treat:”
With reference point embryo biopsy, days-5/6 biopsies
demonstrated significantly higher ongoing pregnancy
rates than day-3 biopsies. Yet, even the authors noted
that this statistical difference completely evaporated once
comparisons were made with reference point embryo
transfer, where days-5/6 biopsies no longer demonstrated
outcome advantages over day-3 biopsies in terms of on-
going pregnancy rates.
This statistical observation, therefore, represents the
most convincing evidence in the manuscript of Harton
et al. that days-5/6 embryo biopsies do not appear to
improve IVF outcomes in comparison to day-3 embryo
biopsies. Even considering previously noted obvious meth-
odical weaknesses, this study, therefore, offers rather
convincing evidence that a major argument of PGS#2
proponents, almost with certainty, is inaccurate.
This, of course, raises further doubts about the hypoth-
esis that PGS#2 represents a diagnostic clinical improve-
ment over PGS#1, and that PGS#1 failed for technical
reasons. The study by Harton et al., therefore, at minimum
demonstrates that days-5/6 biopsies offer no outcome
advantage over day-3 biopsies. Since, as noted earlier,
embryo culture to blastocyst stage results in definite
and significant clinical as well as cost disadvantages, the
study by Harton et al., indeed, strongly suggests that, if
PGS is to be performed at all as a tool of IVF outcome
improvement, it actually should be performed on day-3
embryos, utilizing new diagnostic platforms for determin-
ation of aneuploidy in full chromosome complements.The repositioning of PGS#2 marketing
Since published studies have so far been unable to prove
pregnancy outcome benefits for PGS#2, proponents of
the procedure have started to promote the procedure
for new indications. A prime example is the alleged
PGD#2-driven ability of reducing twin pregnancies by
facilitating embryo selection for elective single embryo
transfer (eSET) [27].Forman et al. recently reported that this represented
the primary benefit of a clinical PGS#2 trial [27]. Their
Clinical Trial Registration (#NCT011408433) at [27] notes,
however, that the original primary intent of the study was
improvement of IVF pregnancy rates. As this failed, their
original intent was replaced by the listed secondary goal of
the study, the reduction of twin pregnancies via eSET. We
would argue that under generally accepted study reporting
guidelines, such an unreported switch in study goals is
inappropriate.
Specifically, the original Clinical Trial Registration lists
as Primary Outcome Measures: (i) Live birth rate per
randomized patient; and (ii) Comparative live birth rates
of patients with elective single embryo transfer (eSET)
of chromosomally normal embryos (after utilizing 24-
chromosome copy analysis, given the acronym Comprehen-
sive Chromosome Screening, CCS) and 2-embryo (2-ET)
transfer without CCS. Only their Secondary Outcome
Measures related to the risk of twinning. The published
paper, however, does not refer to pregnancy rates in title
of manuscript, and barely refers to pregnancy rates in
the body of the manuscript.
The manuscript, however, describes itself in the title as
a randomized controlled trial of single blastocyst stage
embryo transfer, and it really is neither. The study design
per initial registration (see above) was for a non-inferiority
trial, demonstrating non-inferiority of transfer of a single
embryo after PGS#2 in comparison to transfer of two
embryos at blastocyst stage without trophectoderm
biopsy and aneuploidy determination. Moreover, at 20%
non-inferiority, the trial was set to demonstrate inferiority
only if any difference between these two treatment arms
exceeded 20%, a clinically potentially highly significant
difference. In other words, even 19.9% inferiority in clinical
outcome with transfer of a single euploid embryo would,
still, have fallen within the excessive non-inferiority param-
eters set by the authors.
Pregnancy rates with single embryo transfer were, how-
ever, in absolute terms actually 4.4% lower and in relative
terms 7.2% lower than with chromosomally untested
double embryo transfer. Basically leaving this fact unad-
dressed in their manuscript, and claiming non-inferiority,
the authors concentrated on above described secondary
goal of their study, assessing in the literature already well-
described effects of single embryo transfer on reducing
twin pregnancy rates in association with IVF.
Reducing twin pregnancies represent a distinctively sep-
arate subject of considerable complexity from the primary
goal of PGS#2 to improve IVF pregnancy and delivery
rates. We, indeed, have extensively addressed the concept
of single embryo transfer in the literature [28,29]. As a
topic of further discussion, it is beyond the framework of
this commentary. Only so much: Since the Clinical Trial
Registry does not consider reduction of twin risks as the
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the patients’ primary intent (and informed consent) in
participating in this trial was reduction of twinning
risks. Much more likely, their participation was soli-
cited with the intent of improving IVF pregnancy and
delivery chances, a proposition infertility patients are
supportive of [13].
As outcome reporting was, again, not based on “intent
to treat”, reported IVF pregnancy rates are, in addition,
inflated. Patients who did not have at least one euploid
embryo for embryo transfer (in controls at least two
blastocyst-stage embryos) were removed from outcome
considerations. Consequently, 33/205 (16.1%) of original
study participants were removed after the study’s initial
selection criteria already excluded poor prognosis pa-
tients above age 42 years (AMH < 1.2 ng/mL and FSH >
12.0 IU/L). Selection biases in favor of favorable patients,
thus, occurred in this study at three separate stages.
An analysis by “intent to treat”, would, therefore, likely
further have lowered pregnancy rates by approximately
16.1%, resulting in pregnancy rates of 51.6% and 54.6%,
respectively, for study and control groups, both rather
unremarkable pregnancy rates for so highly selected,
young patients. Indeed, these rates are lower than those
reported by Schoolcraft’s group years ago in similarly
selected women after blastocyst-stage eSET without any
form of PGS [30].
As in many previously reported studies, single embryo
transfer thus, even after PGS#2, resulted in lower IVF
pregnancy rates than double-blastocyst stage embryo
transfer with chromosomally unscreened embryos. Single
embryo transfer, therefore, apparently will always reduce
twin pregnancies but also always result in lower pregnancy
rates than a 2-embryo transfer, raising significant ques-
tions about the utility of performing chromosomal analysis
of embryos in even favorably selected women. At mini-
mum, these data suggest that even favorably selected
patients, still, require further selection to identify sub-
populations who may benefit from PGS#2 [12,18]. Who
these patients are (if such women, indeed, exist) remains,
however, to be determined.
Even a suggestion that PGS#2 is responsible for the
observed reduction in twin pregnancies in this study
appears incorrect. Above noted study from Schoolcraft’s
group claimed such a benefit from single embryo transfer
already in 2004 [30]. Only a direct comparison of single
embryo transfer with and without PGS#2 would allow for
such a conclusion.
The study, in addition, did not meet even minimum
criteria for a non-inferiority trial design. Interested readers
on the subject of non-inferiority trials are referred to
authoritative recent references, which in detail explain
the complexities and requirements for such studies
[31,32]. One also has to wonder about the purpose of anon-inferiority trial when the purpose of PGS is selection
of euploid embryos to improve implantation and preg-
nancy rates [33]. Non-inferiority, therefore, becomes irrele-
vant; superiority should be the desired and investigated
end point.
The paper by Forman et al., thus, paradoxically presents
another very convincing clinical trial demonstrating that,
even in highly favorably selected young women, PGS#2
appears ineffective in its primary goal, of improving IVF
pregnancy rates.
Conclusions
We spent extensive time commenting on the manuscripts
by Harton et al. [20] and Forman et al. [27] because both
of these manuscripts received, in our opinion, much too
uncritical reception by the IVF community. The conclu-
sions of the manuscript by Forman et al., to our surprise,
indeed, not only received editorial support [14] but were
even endorsed by the American College of Obstetricians
and Gynecologists (ACOG), which went to the extraordin-
ary length of issuing a supportive opinion statement to the
media [34].
This is especially surprising since policy statements,
declaring PGS as ineffective in improving clinical preg-
nancy rates and reducing miscarriages, by the American
Society for Reproductive Medicine (ASRM) [35], the
European Society for Human Reproduction and Embry-
ology (ESHRE) [36] and the British Fertility Society [37],
issued after the failure of PGS#1 was recognized, still stand.
Mastenbroek et al., who were so crucial in reducing the
worldwide utilization of PGS#1 [1], have since confirmed
the ineffectiveness of PGS (largely PGS#1) in a systemic re-
view and meta-analysis [38]. More recently, Mastenbroek
also cautioned against the premature introduction of
PGS#2 [39]. The recently published studies of Harton
et al. [20] and Forman et al. [27] add further oil to the fire.
Considering that these authors, despite utilization of
trophectoderm biopsy and state-of-the-arts aneuploidy
testing, still, in even highly favorable patient populations,
were unable to improve pregnancy rates suggests a quickly
shrinking population base in which PGS may be effective.
Indeed, one has to accept the increasing likelihood that
the underlying paradigm for PGS, simply, may not work.
The procedure just appears to increase costs and com-
plexities of IVF. Its utilization, at present, should therefore
be acknowledged as highly experimental and refuted in
routine IVF care. Interestingly, Twisk et al. already in 2008
came to similar conclusions [7].
PGS#1 caused significant harm to thousands of patients,
as noted before [5]. We should not allow it to happen
again!
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